GlucoTrack (GCTK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
31 Jul, 2026Executive summary
Special Meeting called to approve two major stock issuance proposals and an adjournment proposal.
Both stock issuances relate to compliance with Nasdaq Listing Rule 5635(d) and could exceed 20% of outstanding shares.
Board unanimously recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposal 1 seeks approval for full issuance of shares under the ELOC Purchase Agreement with White Lion Capital, including commitment shares and warrant shares.
Proposal 2 seeks approval for full issuance of shares upon conversion of Bridge Notes and exercise of Bridge Warrants issued to Bridge Investors.
Proposal 3 allows adjournment of the meeting to solicit additional proxies if needed for quorum or approval of Proposals 1 or 2.
Board recommends voting “FOR” all three proposals.
Shareholder proposals for the next annual meeting must be received by March 19, 2027, to be considered.
Board of directors and corporate governance
Voting rights: one vote per share; no dissenters' rights for these proposals.
Quorum requires one third of outstanding shares present virtually or by proxy.
Proxy solicitation costs will be borne by the company, with a proxy solicitor engaged.
Latest events from GlucoTrack
- Shareholders will vote on director elections, executive pay, a reverse stock split, and warrant inducement.GCTK
Proxy filing17 Jul 2026 - Shareholders will vote on director elections, executive pay, a reverse split, and warrant inducement.GCTK
Proxy filing17 Jun 2026 - Net loss narrowed, IDE submitted, but liquidity and Nasdaq risks threaten operations.GCTK
Q1 202614 May 2026 - Implantable CBGM delivers 3-year monitoring, high accuracy, and wearable-free comfort.GCTK
Investor presentation8 May 2026 - Q2 net loss rose to $4.5M, cash at $159K, with ongoing funding and Nasdaq compliance risks.GCTK
Q2 202414 Apr 2026 - Net loss increased to $5.1M in Q3 2024, with cash needs unmet without further financing.GCTK
Q3 202414 Apr 2026 - Improved net loss and cash position support 2026 clinical trial launch for implantable CBGM.GCTK
Q4 202530 Mar 2026 - All meeting proposals, including major share issuances, were approved by stockholders.GCTK
EGM 202612 Mar 2026 - Votes sought for major stock issuances, auditor ratification, and potential meeting adjournment.GCTK
Proxy Filing9 Feb 2026